Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias Rummel, N. Niederle, Georg Maschmeyer, Gamal-Andre Banat, Ulrich von Grünhagen, Christoph Losem, Dorothea Kofahl-Krause, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Eckhart Weidmann, Heinz Dürk, Harald Balló, Martina Stauch, Fritz Roller, Juergen Barth, Dieter Hoelzer, Axel Hinke, Wolfram Brugger
The Lancet, 2013
Abstract
An abstract is not available for this record. Please visit the publisher website for more details.